German drugmaker CureVac has launched a phase 2 trial to evaluate its COVID-19 vaccine candidate CVnCoV in Panama and Peru.

The study aims to confirm the messenger RNA vaccine’s safety and efficacy in adults at different dose levels. The trial will enroll 690 patients in two age groups, ages 18 to 60 and ages 61 and over, who will receive two vaccinations 28 days apart.

Pending the results of the study, the company expects to begin a late-stage trial of the vaccine in 30,000 participants in the fourth quarter of 2020.